(Total Views: 609)
Posted On: 12/14/2020 4:12:45 PM
Post# of 150100
By royalties I mean we are providing non-commercial grade leronlimab to them and they are giving us money in return. As you said, we are selling leronlimab to them. I haven't seen a copy of the license agreement, but that's usually how it works: either a set price or royalty. I don't see how or why they would buy it "across the counter" if you mean paying retail price for commercial grade drug.
From the last 10-K:
From the PR:
So, Nader was definitely hyping this as some revenues coming in (whatever you chose to call them), and InCellDx would be paying us. We will not be paying them.
From the last 10-K:
Quote:
Subsequently, we entered into an exclusive worldwide licensing agreement with IncellDX to sell non-commercial grade quantities of PA-14 or PRO 140 for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
From the PR:
Quote:
“The execution of the definitive agreement with IncellDX marks an important milestone for CytoDyn as it puts us firmly on pace to generate our first revenues over the course of the next several months,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D.
So, Nader was definitely hyping this as some revenues coming in (whatever you chose to call them), and InCellDx would be paying us. We will not be paying them.
(1)
(0)Scroll down for more posts ▼
